vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Navitas Semiconductor Corp (NVTS). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $8.6M, roughly 1.2× Navitas Semiconductor Corp). On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -38.7%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -35.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Navitas Semiconductor Corp is a leading global semiconductor firm specializing in gallium nitride (GaN) power integrated circuits. Its high-efficiency, compact power solutions serve consumer electronics, electric vehicles, renewable energy, and industrial sectors, with clients spanning North America, Asia, and Europe.
ABUS vs NVTS — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $8.6M |
| Net Profit | $2.5M | — |
| Gross Margin | — | 98.6% |
| Operating Margin | 13.9% | -260.6% |
| Net Margin | 23.5% | — |
| Revenue YoY | 522.2% | -38.7% |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $8.6M | ||
| Q4 25 | — | $7.3M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | $10.7M | $14.5M | ||
| Q1 25 | — | $14.0M | ||
| Q4 24 | — | $18.0M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | — | $20.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-31.8M | ||
| Q3 25 | — | $-19.2M | ||
| Q2 25 | $2.5M | $-49.1M | ||
| Q1 25 | — | $-16.8M | ||
| Q4 24 | — | $-39.9M | ||
| Q3 24 | — | $-18.7M | ||
| Q2 24 | — | $-22.3M |
| Q1 26 | — | 98.6% | ||
| Q4 25 | — | 38.1% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | — | 16.1% | ||
| Q1 25 | — | 37.9% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | — | 39.7% | ||
| Q2 24 | — | 39.0% |
| Q1 26 | — | -260.6% | ||
| Q4 25 | — | -567.3% | ||
| Q3 25 | — | -192.0% | ||
| Q2 25 | 13.9% | -149.4% | ||
| Q1 25 | — | -180.5% | ||
| Q4 24 | — | -216.9% | ||
| Q3 24 | — | -133.6% | ||
| Q2 24 | — | -152.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | -436.1% | ||
| Q3 25 | — | -190.2% | ||
| Q2 25 | 23.5% | -338.7% | ||
| Q1 25 | — | -120.1% | ||
| Q4 24 | — | -221.7% | ||
| Q3 24 | — | -86.4% | ||
| Q2 24 | — | -109.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | $-0.14 | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | $0.01 | $-0.25 | ||
| Q1 25 | — | $-0.09 | ||
| Q4 24 | — | $-0.22 | ||
| Q3 24 | — | $-0.10 | ||
| Q2 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $221.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $420.0M |
| Total Assets | $103.3M | $481.4M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $221.0M | ||
| Q4 25 | — | $236.9M | ||
| Q3 25 | — | $150.6M | ||
| Q2 25 | $37.4M | $161.2M | ||
| Q1 25 | — | $75.1M | ||
| Q4 24 | — | $86.7M | ||
| Q3 24 | — | $98.3M | ||
| Q2 24 | — | $111.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $420.0M | ||
| Q4 25 | — | $443.7M | ||
| Q3 25 | — | $371.0M | ||
| Q2 25 | $83.0M | $388.9M | ||
| Q1 25 | — | $341.8M | ||
| Q4 24 | — | $348.0M | ||
| Q3 24 | — | $380.8M | ||
| Q2 24 | — | $388.1M |
| Q1 26 | — | $481.4M | ||
| Q4 25 | — | $500.5M | ||
| Q3 25 | — | $430.2M | ||
| Q2 25 | $103.3M | $449.4M | ||
| Q1 25 | — | $370.8M | ||
| Q4 24 | — | $390.0M | ||
| Q3 24 | — | $419.4M | ||
| Q2 24 | — | $439.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-8.1M | ||
| Q3 25 | — | $-10.0M | ||
| Q2 25 | $-15.7M | $-11.2M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $-10.2M | ||
| Q3 24 | — | $-13.7M | ||
| Q2 24 | — | $-15.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-8.2M | ||
| Q3 25 | — | $-10.7M | ||
| Q2 25 | — | $-11.9M | ||
| Q1 25 | — | $-13.6M | ||
| Q4 24 | — | $-10.8M | ||
| Q3 24 | — | $-14.3M | ||
| Q2 24 | — | $-17.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -111.8% | ||
| Q3 25 | — | -106.1% | ||
| Q2 25 | — | -82.2% | ||
| Q1 25 | — | -96.8% | ||
| Q4 24 | — | -59.8% | ||
| Q3 24 | — | -65.9% | ||
| Q2 24 | — | -87.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | 0.0% | 4.7% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | — | 13.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
